Vascular Dementia Market Report 2026

The vascular dementia market size has grown rapidly in recent years. It will grow from $3.27 billion in 2025 to $3.65 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increasing incidence of stroke-related cognitive decline, rising prevalence of hypertension and diabetes, expansion of neurological research programs, improved diagnostic awareness, growth in hospital-based dementia care.

The vascular dementia market size is expected to see rapid growth in the next few years. It will grow to $5.63 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing aging population, rising investments in neurological drug development, growing adoption of digital health monitoring tools, expansion of precision medicine approaches, increasing focus on long-term cognitive health management. Major trends in the forecast period include increasing focus on early diagnosis of cognitive disorders, rising integration of digital cognitive assessment tools, growing research into vascular-related neurodegeneration, expansion of personalized treatment approaches, enhanced emphasis on preventive care strategies.

The increasing prevalence of cardiovascular disease is anticipated to drive growth in the vascular dementia market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and hypertension. The rising incidence of cardiovascular diseases is attributed to factors such as unhealthy lifestyle choices, poor diet, physical inactivity, elevated stress levels, aging populations, and a rise in risk factors like obesity, diabetes, and hypertension. Cardiovascular disease contributes to the development of vascular dementia by reducing blood flow to the brain, which causes cognitive decline and damages brain cells due to decreased oxygen and nutrient supply. For instance, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including around 4 million men and 3.6 million women. These conditions account for about 27% of all deaths in the UK, equating to more than 170,000 deaths annually, or roughly 480 deaths per day, which is approximately one death every three minutes. Therefore, the rising prevalence of cardiovascular diseases is driving the vascular dementia market.

Major companies operating in the vascular dementia market are concentrating on the development of novel therapies, including multimodal approaches, to maintain their market position. Multimodal therapies involve the combination of multiple treatment strategies, such as medications, physical therapy, and psychological interventions, to provide comprehensive management of a condition. For instance, in January 2023, Moleac, a Singapore-based biopharmaceutical company, launched CognivAiD, an evidence-based treatment specifically developed for vascular dementia (VaD), a condition with limited therapeutic options. The product combines active extracts from ginkgo, ginseng, and saffron, which have demonstrated the ability to significantly slow cognitive decline in VaD patients. CognivAiD’s unique multimodal mechanism targets key aspects of vascular dementia, including vascular protection, vasoregulation, and neuroinflammation. Supported by extensive clinical studies and a strong safety profile, CognivAiD offers a promising treatment option for individuals affected by VaD.

In November 2023, Merck, a US-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undisclosed sum. Through this acquisition, Merck aims to accelerate the development of innovative small-molecule therapies targeting neurodegenerative diseases, including Parkinson’s disease and dementia. Caraway Therapeutics Inc. is a US-based biopharmaceutical firm specializing in drug discovery and development for dementia.

Major companies operating in the vascular dementia market are Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix Corp, Cyclerion Therapeutics Inc, CSPC‑NBP Pharma, Johnson & Johnson Services Inc, Materia Medica Holding, Eisai Co Ltd, Shineway Pharmaceutical, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Pfizer Inc, Biogen Inc, Novartis AG, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals, Zydus Cadila, Eli Lilly and Company.

North America was the largest region in the vascular dementia market in 2025. The regions covered in the vascular dementia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the vascular dementia market by increasing costs of imported pharmaceutical ingredients, diagnostic imaging systems, laboratory equipment, and digital monitoring technologies used in disease management. Healthcare providers in North America and Europe are most affected due to reliance on imported medical products, while Asia-Pacific faces higher costs for advanced diagnostic tools. These tariffs are contributing to higher treatment and monitoring expenses. However, they are also encouraging local pharmaceutical manufacturing, regional clinical research initiatives, and domestic production of diagnostic solutions, strengthening healthcare supply chains.

The vascular dementia market research report is one of a series of new reports that provides vascular dementia market statistics, including vascular dementia industry global market size, regional shares, competitors with a vascular dementia market share, detailed vascular dementia market segments, market trends and opportunities, and any further data you may need to thrive in the vascular dementia industry. This vascular dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vascular dementia is a form of cognitive impairment caused by reduced blood flow to the brain, commonly resulting from strokes or other vascular disorders, and leads to memory loss and difficulties with thinking. Management of vascular dementia focuses on addressing underlying vascular conditions such as hypertension, diabetes, and high cholesterol, along with adopting healthy lifestyle practices to support brain health and slow the progression of the condition.

The main products used in vascular dementia include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies represent a segment of vascular dementia treatment in which antibodies are developed to target specific proteins or molecules associated with the disease. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are intended for end users such as hospitals and clinics, rehabilitation centers, and specialty clinics.

The vascular dementia market consists of revenues earned by entities providing services such as diagnosis, treatment, care management, and support for individuals. The market value includes the value of related goods sold by the service provider or included within the service offering. The vascular dementia market includes sales of assistive devices, cognitive enhancers, and diagnostic tools. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including healthcare providers, wholesalers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.